AN2 Therapeutics, Inc. (ANTX) Research

AN2 Therapeutics, Inc. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of treatments for uncommon, long-term, and severe infectious conditions. A key focus of their pipeline is epetraborole, an investigational oral medication designed for once-daily administration to individuals battling chronic non-tuberculous mycobacterial lung disease. This enterprise was established in 2017 and operates from its headquarters situated in Menlo Park, California.

Market snapshot

Symbol
ANTX
Price
$5.00
Day change
+2.04%
Market cap
$137.0M
P/E ratio
-4.93x
52-week range
1-6.91
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$9.00

Recent news

  • The Healthcare M&A Wave

    In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.

Peer companies

  • Boundless Bio, Inc. (BOLD)
  • iBio, Inc. (IBIO)
  • Intensity Therapeutics, Inc. (INTS)
  • Iterum Therapeutics plc (ITRM)
  • NextCure, Inc. (NXTC)
  • Pluri Inc. (PLUR)
  • Plus Therapeutics, Inc. (PSTV)
  • Q32 Bio Inc. (QTTB)

Recent insider activity

  • Williams Sarah Joanne — S-Sale (265 shares) on 2026-05-29
  • Aziz Kabeer — A-Award (3775 shares) on 2026-04-10
  • Marks Gilbert Lynn — A-Award (3775 shares) on 2026-04-10
  • Martin Patricia A. — A-Award (1192 shares) on 2026-04-10
  • Day Lucy — A-Award (82300 shares) on 2026-03-19

Open AN2 Therapeutics, Inc. (ANTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.